Articles tagged with Enzyme Inhibitors
Researchers at the Francis Crick Institute and UCL have identified a gene that causes heart defects in Down syndrome, a condition resulting from an extra copy of chromosome 21. Reducing the overactivity of this gene partially reversed these defects in mice, setting the scene for potential future therapies.
A team of scientists has identified a previously unrecognized control point in DNA repair processes, which could lead to novel cancer therapies by inhibiting the repair of damaged cancer cells. The newly discovered GSE1-CoREST complex contains three enzymes that control DNA repair and may form the basis for improved cancer treatments.
Researchers from Brazil have discovered two novel peptides with biotechnological potential in the venom of the pit viper Cotiara and the South American bushmaster. The peptides, including Bc-7a and Lm-10a, show promise as potential treatments for high blood pressure.
Researchers have gained a deeper understanding of the nuanced roles of JAK inhibitors in inflammation across various cell types and tissues. The study reveals that activating JAK1 signaling has tissue-specific effects, including an unexpected immunoregulatory role in lung sensory neurons, which suppresses lung inflammation.
A clinical trial found that an experimental drug, BI 690517, reduced albuminuria in 70% of patients when paired with a standard-care medication. The study also showed that the combination of the two drugs mitigated the risk of hyperkalemia.
A team of Kyoto University researchers found that macrophages produce granulomas through a hyperactive metabolic pathway called the pentose phosphate pathway. Inhibition of this pathway showed therapeutic efficacy in reducing granuloma formation in vitro and in mouse tissue models.
Researchers found that 1,8-cineole inhibits inflammatory pathways in the gut, while ginsenoside Rk2 alleviates liver inflammation and restores intestinal barrier function. Another compound, specnuezhenide, modifies gut microbiota and has potential to inhibit colorectal tumor growth.
Researchers developed novel small molecule inhibitors of CPSF3, a key regulator of transcription termination in ovarian cancer cells. These inhibitors exhibited potent antiproliferative effects and suppressed tumor growth in vivo.
Researchers at Beth Israel Deaconess Medical Center have made a groundbreaking discovery that inhibiting a specific enzyme can halt the progression of Parkinson's disease in a mouse model. The findings suggest that reducing USP30 may slow or prevent PD progression, paving the way for novel therapeutics.
Researchers found that FAAH inhibition reduced breast cancer growth in immunodeficient mice and induced apoptosis of breast cancer cells. The combination of FAAH inhibitors and endocannabinoids was the most effective treatment approach.
A new antibody created by Cold Spring Harbor Laboratory researchers may offer an effective treatment for some breast cancers. The antibody targets the PTPRD enzyme, which is overabundant in certain breast cancers and helps them spread.
A team of researchers at Kyoto University has found that a deficiency in the enzyme B4GALT3 inhibits tumor growth in mice. The study shows that reduced glycosylation on T cell surfaces correlates with increased CD8+ immune cells infiltrating tumors.
A new study reveals that mosquito eggs can tolerate extended desiccation by changing their metabolic pathway. By rewiring their polyamine and lipid metabolism, the eggs become more resistant to dehydration. This finding provides potential new ways to control the spread of Zika virus.
Researchers classify UGDH as a molecular indicator of tumor progression in multiple cancer types, describing its involvement in key canonical cancer signaling pathways. Methods to inhibit UGDH and its downstream products are also identified.
Researchers at Baylor College of Medicine developed a new compound called d16 that can reduce tumor growth and overcome therapeutic resistance in mutant p53-bearing cancers. The compound, which targets the DNA2 enzyme, shows promise as a potential combination therapy for difficult-to-treat cancers.
Preclinical data shows GP-2250's antineoplastic activity in pancreatic tumor cell lines, reducing ATP levels and inhibiting NF-kB. The compound targets aerobic glycolysis, a hallmark of cancer metabolism, providing a potential treatment for various cancers.
Researchers have developed a new approach to treating herpes by inhibiting an enzyme that releases newly formed virus particles from infected cells. The inhibitors, made of oligosaccharides, significantly reduce the spread of the virus and may also impede cancer metastasis.
Researchers have identified a cluster of neurons in the hypothalamus called GABRA5 that regulates energy expenditure. Astrocytes control this cluster, producing tonic GABA that inhibits it, leading to weight gain.
Scientists at CU Anschutz Medical Campus discover that long-term potentiation requires structural functions of CaMKII, not enzymatic actions. This breakthrough opens the door to therapeutic use of inhibitors targeting only CaMKII activity.
A study published in Cell Chemical Biology reveals that cannabidiol (CBD) from hemp acts as a molecular switch in innate immune cells to promote the biosynthesis of inflammation-resolving lipid mediators. This finding holds promise for developing new therapeutic strategies to treat inflammatory diseases.
A team of KAUST researchers has found a critical protein that regulates cell division and proliferation in breast cancer and leukemia. Their work clears the way for the development of targeted drugs by refuting recent challenges to their approach.
A new study demonstrates that a pill inhibiting a gut enzyme can protect mice from IBD symptoms and preserve intestinal barrier function. The experimental GCPII-inhibiting drug was shown to improve stool consistency, reduce rectal bleeding and inflammation, with no apparent side effects.
A new antibiotic strategy has been found to defeat gram-negative bacteria like Salmonella and E. coli by interfering with the outer lipid layer of the bacteria. The compound, LPC-233, is a small molecule that works fast and is durable in animal tests, with potentially vital applications against stubborn urinary tract infections.
Researchers developed innovative techniques to treat challenging cancers and manage therapy side effects. Inhibitors targeting PRMT5, a histone-modifying enzyme, alleviated cisplatin-induced hearing loss, while nano-pills delivered combination drugs to liver cancer cells.
A new multiplex assay has been developed to assess activated p300/CBP in circulating prostate tumor cells, revealing correlations with clinical outcomes and potential therapeutic targets for castration-resistant prostate cancer. The study found that patients with upregulated p300/CBP activity had shorter response times to ARSI therapy.
Researchers at Children's Hospital of Philadelphia found that NSAIDs exacerbate C. difficile infections by disrupting epithelial cell mitochondria, sensiting them to toxins. The study shows that NSAIDs and C. difficile toxins work synergistically to increase virulence, leading to increased disease severity and mortality.
Rice University chemist Han Xiao has won a $3.2 million research grant from the National Cancer Institute to develop an epigenetic inhibitor targeting bone metastasis. The drug, based on existing bisphosphonates, aims to prevent cancer cells from spreading to other organs without affecting normal tissues.
Researchers at Helmholtz Munich discovered that DHODH inhibitors sensitize cancer cells to ferroptosis by inhibiting ferroptosis suppressor protein-1 (FSP1), not DHODH itself. This finding confirms the crucial role of FSP1 in ferroptosis surveillance and opens up new avenues for developing effective cancer therapies.
Scientists have gained high-res structural insights into a key bacterial enzyme to develop new drugs that target its weaknesses and suppress disease-causing bacteria. The enzyme Lnt is not found in humans and has huge potential as a therapeutic target with fewer side effects for patients.
Researchers found that intravenous treatment with MK-3402, a metallo-beta-lactamase inhibitor, can effectively fight antimicrobial resistance in certain bacteria. The studies suggest that dosing three times per day provides adequate blood levels to block bacterial enzymes.
Researchers have found a compound that can prevent cisplatin-induced renal toxicity and improve the outcomes of cancer treatment. The aromatic ketone 2',4',6'-trihydroxyacetophenone (THA) inhibits the CCBL1-mediated metabolism of cisplatin, reducing its toxic effects without affecting its potency.
A study found that young women are more likely to experience adverse outcomes and rehospitalization after a heart attack, with non-cardiac hospitalizations showing the most significant disparity. Researchers highlight the need for public awareness and sex-specific post-heart attack care.
Researchers at Texas Biomedical Research Institute have identified a potential host-directed therapy targeting the immune system to bolster the body's ability to control TB infection. Blocking IDO enzyme helped nonhuman primates completely eliminate active TB infection, improving health metrics compared to antibiotics alone.
Researchers have discovered a novel medication that effectively treats a rare hereditary muscle disease causing complete immobility and death. The treatment has also shown promise in treating severe statin-associated myopathy, with improved symptoms in patients awaiting treatment.
A remote hypertension program, operated by Mass General Brigham, successfully supported patients through the COVID-19 pandemic in achieving their blood pressure goals. Participants who enrolled during the pandemic reached and maintained their goal blood pressures an average of two months earlier than in the pre-pandemic period.
Researchers at Washington State University found that CBD inhibits a key enzyme for nicotine metabolism, slowing down its effects and allowing smokers to wait before feeling the urge to smoke. The study suggests that CBD could be a useful tool in reducing harm from smoking and quitting nicotine addiction.
Researchers at Nagoya University have identified 2,6-dihalopurines as a new class of stomatal opening inhibitors, potentially involving LRX3-5 and RALF peptide. This discovery may lead to the development of new agrochemicals and chemical biology research applications.
Researchers at EMBL Grenoble have discovered that THC inhibits the human enzyme autotaxin, which is involved in cancer, inflammation, and pulmonary fibrosis. This finding provides new molecular insights into the therapeutic effects of medical cannabis.
Researchers at the University of Illinois Chicago have discovered a small molecule capable of manipulating an immune process that plays a crucial role in cancers and autoimmune diseases. The newly identified enzyme inhibitor could enhance immune responses against tumors, increasing their visibility to T-cells.
Researchers at the University of Würzburg have found that fluoxetine and its analogue AKS466 can inhibit SARS-CoV-2 coronavirus replication by trapping it in lysosomes and suppressing acid ceramidases, a new potential target for antiviral therapy.
Researchers generated simple kidney-like structures called organoids and used them to identify potential drugs for adult-onset polycystic kidney disease. They found nine compounds that inhibited cyst growth without stunting overall growth.
Researchers at Colorado State University have found a way to alter the type of synapses between brain cells using enzymes. This breakthrough could lead to new treatments for brain disorders caused by faulty synaptic information processing and exchange.
A team from Goethe University has identified the spatial structure of the mannitol-synthesizing enzyme MtlD in Acinetobacter baumannii, which is crucial for its survival. This discovery could lead to the development of customized substances to inhibit the enzyme and combat this hospital pathogen.
A breakthrough discovery has identified a novel approach to tackle metabolic diseases by inhibiting a liver enzyme that regulates appetite and energy expenditure. The treatment, which stabilizes key proteins in the blood, resulted in significant weight loss and improved insulin sensitivity in obese mice.
Researchers have developed a new compound that prevents and treats COVID-19 caused by the Delta variant in mice. The compound, N-0385, blocks entry at the cell surface without causing detectable cell damage.
Researchers have identified a novel enzyme that catalyzes the formation of glycosidic bonds in complex sugar moieties. The discovery provides fresh insights into carbohydrate metabolism and offers a breakthrough for the synthesis of sugar chains, which play key roles in various biological processes.
A team of UTSA researchers has developed an innovative inhibitor that blocks the effects of cytochrome P450 8B1, a key enzyme linked to cholesterol absorption and obesity. The treatment shows promise in reducing glucose levels without affecting body weight, offering potential relief from obesity-associated metabolic disorders.
A natural product from the dried root of Sophora flavescens, combined with an enzyme inhibitor, has been found to reduce neuroinflammation in a mouse model of Parkinson's disease. The compound kurarinone may provide hope for alleviating symptoms of the incurable disorder.
Researchers discovered how a single mutation in an enzyme enables bacteria to evade antibiotics by using mirrored structures. This finding has implications for developing more resilient inhibitors and proactive drug designs.
Researchers from the University of Tsukuba have discovered that certain flavonoids inhibit an enzyme involved in the formation of a key insect hormone in the yellow fever mosquito. Flavonoids, found in plants and other organisms, also show larvicidal activity against mosquitoes.
A team of scientists at Brookhaven National Laboratory has identified a molecule with significant potential to disable the COVID-19 virus. The molecule was discovered using high-throughput virtual screening and laboratory experiments, and its ability to bind to the virus's main protease was confirmed through structural studies.
Researchers have identified two new compounds that can inhibit the replication of human herpesviruses by targeting specific enzymes. This breakthrough offers new opportunities for developing agents against herpesviruses, which are currently difficult to treat effectively.
A new study by the University of North Carolina at Chapel Hill and an international team finds that triclosan triggers gut inflammation in mice. The researchers identified specific bacteria and enzymes that drive this damage, but also developed a microbiome-targeted inhibitor to block triclosan processing, preventing colitis.
A new anti-diabetic compound, Montbretin A (MbA), has been approved by Health Canada for Phase 1 human trials. MbA works by inhibiting the alpha-amylase enzyme, slowing down starch breakdown and reducing blood sugar spikes in Type 2 diabetics.
Researchers discovered that leukemia cells immediately unresponsive to treatment have high levels of SAMHD1, while those with acquired resistance use the enzyme DCK to activate nucleoside analogues. This finding may lead to better cancer therapies.
Researchers at TTUHSC have identified novel targets for treating stroke, focusing on enhancing neurolysin activity. The study discovered small molecules that can selectively enhance the activity of neurolysin, which showed promise in reducing damage to the brain after a stroke.
Researchers at the University of Alabama at Birmingham have identified DOT1L as a potential therapeutic target for ovarian cancer. Inhibitors of the DOT1L enzyme showed promise in reducing tumor growth and improving survival rates by stimulating pro-tumorigenic metabolic pathways and blocking apoptosis.
The article highlights available treatment alternatives for mild and serious COVID-19 cases, as well as vaccine options that can confer immunity to vaccinated individuals. Researchers conclude a combinatorial therapy should be designed with both immunizations and small compounds.
A randomized trial found that continuing common heart medications in COVID-19 patients did not negatively impact their health. The trial enrolled 659 patients and showed no significant difference in the number of days alive and out of hospital between those who continued and suspended their medications.
Researchers have developed first-in-class inhibitors of the NSD1 protein, a key enzyme linked to several types of cancer. The lead compound, BT5, showed promising activity in leukemia cells with the NUP98-NSD1 chromosomal translocation.